这篇文章不错，转发给_老虎社区_美港股上老虎

2023-11-12

这篇文章不错，转发给大家看看

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":240591996289040,"tweetId":"240591996289040","gmtCreate":1699756802905,"gmtModify":1699756804506,"author":{"id":3544062858019296,"idStr":"3544062858019296","authorId":3544062858019296,"authorIdStr":"3544062858019296","name":"惜旧拾缘","avatar":"https://static.tigerbbs.com/8d2ad3ecb48dd84f5519ce6c64def10c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","htmlText":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/240591996289040","repostId":2382711635,"repostType":2,"repost":{"id":"2382711635","kind":"news","pubTimestamp":1699753981,"share":"https://www.laohu8.com/m/news/2382711635?lang=&edition=full","pubTime":"2023-11-12 09:53","market":"us","language":"zh","title":"“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2382711635","media":"医药笔记","summary":"司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。心血管风险整体降低15%，心血管死亡风险降低15%，心衰复合终点风险降低18%，全因死亡风险降低19%。今年可谓司美格鲁肽的爆发之年，减肥药供不应求一再扩大产能，CKD疗效优异提前终止三期临床，心血管获益大规模三期临床大获成功等。此次MACE三期临床的成功，意味着司美格鲁肽坐实心血管获益效果，为其长期增长再添助力。","content":"<html><head></head><body><p>司美格鲁肽坐实心血管获益效果。</p><h2 id=\"id_3346759412\" style=\"text-align: start;\">Armstrong</h2><p style=\"text-align: justify;\">2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6a86b7b06ac4d42ec2c47cf87bd85b2\" tg-width=\"640\" tg-height=\"463\"/></p><p style=\"text-align: justify;\">SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3db937f6536f84c11f4b6f18ccad6a34\" tg-width=\"640\" tg-height=\"360\"/></p><p style=\"text-align: justify;\">NEJM文章发布了更详细的数据分析。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/43755993eda7827eaf29a523c759ea76\" tg-width=\"640\" tg-height=\"331\"/></p><p style=\"text-align: justify;\">患者基线数据如下。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5fa56eeb676f7736d39a4cb165267a8\" tg-width=\"640\" tg-height=\"722\"/></p><p style=\"text-align: justify;\">心血管获益从研究开始很快就显现，因此认为心血管获益不仅仅是因为体重减轻的附带劫夺。心血管风险整体降低15%，心血管死亡风险降低15%，心衰复合终点风险降低18%，全因死亡风险降低19%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8ed2e130360093aa4c1ff6f9371038a0\" tg-width=\"640\" tg-height=\"549\"/></p><p style=\"text-align: justify;\">支持性次要终点数据，非致命心梗风险降低28%，心衰住院或急诊率降低21%等。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/92087a4d142a9d1d11e0cf7daeb8ef31\" tg-width=\"640\" tg-height=\"408\"/></p><p style=\"text-align: justify;\">今年可谓司美格鲁肽的爆发之年，减肥药供不应求一再扩大产能，CKD疗效优异提前终止三期临床，心血管获益大规模三期临床大获成功等。</p><h2 id=\"id_1233387887\" style=\"text-align: start;\">总结</h2><p style=\"text-align: justify;\">诺和诺德基于对代谢疾病深刻理解，聚焦司美格鲁肽的多适应症开发，围绕肝脏、脑、肠道、胰脏，逐一将多个大适应症收入囊中。今年前三季度，司美格鲁肽大卖12亿美元，预计全年超过200亿美元。此次MACE三期临床的成功，意味着司美格鲁肽坐实心血管获益效果，为其长期增长再添助力。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/709429c776f079c08d60865b206e3ff5\" tg-width=\"640\" tg-height=\"353\"/></p><p><br/></p></body></html>","source":"lsy1608539197933","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-12 09:53 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd><strong>医药笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>司美格鲁肽坐实心血管获益效果。Armstrong2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。...</p>\n\n<a href=\"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/903010d990786c782c161cadde49476c","relate_stocks":{},"source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2382711635","content_text":"司美格鲁肽坐实心血管获益效果。Armstrong2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。NEJM文章发布了更详细的数据分析。患者基线数据如下。心血管获益从研究开始很快就显现，因此认为心血管获益不仅仅是因为体重减轻的附带劫夺。心血管风险整体降低15%，心血管死亡风险降低15%，心衰复合终点风险降低18%，全因死亡风险降低19%。支持性次要终点数据，非致命心梗风险降低28%，心衰住院或急诊率降低21%等。今年可谓司美格鲁肽的爆发之年，减肥药供不应求一再扩大产能，CKD疗效优异提前终止三期临床，心血管获益大规模三期临床大获成功等。总结诺和诺德基于对代谢疾病深刻理解，聚焦司美格鲁肽的多适应症开发，围绕肝脏、脑、肠道、胰脏，逐一将多个大适应症收入囊中。今年前三季度，司美格鲁肽大卖12亿美元，预计全年超过200亿美元。此次MACE三期临床的成功，意味着司美格鲁肽坐实心血管获益效果，为其长期增长再添助力。","news_type":1},"isVote":1,"tweetType":1,"viewCount":951,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/240591996289040"}